BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,373.50
- Market cap
- ₹15,934 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 93.9×Sector 41.3×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.
AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
Other business update announcements
All →Cupid Business Update
Cupid Limited entered an exclusive long-term retail arrangement with V2 Retail, securing dedicated space across 425+ stores. Management targets about ₹400 crore incremental revenue within a year.
- Execution
- Long-term arrangement; nationwide product availability targeted by mid-December 2026; revenue expectation within 12 months
Ugro Capital Business Update
UGRO Capital released a social impact study showing 58% of borrowers saw revenue growth after loans. The study was independently conducted with Impactree.
MPS Business Update
MPS Limited's Chairman and CEO, Rahul Arora, participated in a media interaction with CNBC-TV18. The discussion covered Q2FY27 financial results, business performance, and growth outlook.
Exicom Tele-Systems Business Update
Exicom Tele-Systems is consolidating manufacturing by transitioning operations from its Gurugram facility to existing plants in Hyderabad and Solan. The transition aims to optimize infrastructure and is expected to finish by November 15, 2026.
- Execution
- November 15, 2026
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Vishnu Prakash R Punglia Business Update
VPRPL entered an MoU with N.K. Gupta Builders for proposed acquisition at evaluation stage. The deal targets expansion in infrastructure and construction, including Leh & Ladakh.